evipedia.ai
← Back

Humanin for Health & Longevity

Created on 10/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Humanin, a short protein chain made by the cell's energy compartments and sold only as an injectable research chemical, draws interest for longevity. Nobody has ever given it to a person in a reported study. Higher natural levels go with better blood-vessel function and longer-lived families, and exercise raises those levels. In animals, the same cell-protecting action made tumors grow faster and resist treatment. (Full Review)

Protocol

Animal regimen most often cited
HNG 4 mg/kg twice weekly
Intraperitoneal injection in middle-aged mice for 6 to 14 months; no validated human protocol
Route in gray-market practice
Subcutaneous injection
Reconstituted freeze-dried powder, chosen for convenience
Competing approach — raising endogenous output
Exercise
Acute endurance exercise raised plasma humanin and resistance training raised muscle humanin; human rather than animal evidence
Time to effect
Memory (mice)
10 months
Of injections before a memory difference; unknown in people
Muscle humanin (exercise)
12 weeks
Of resistance training before muscle humanin rose in prediabetic men
Balance (mice)
6 months
Of injections before a balance difference

Benefits

Contraindications
  • Anyone with active, recently treated or previously treated cancer
  • Anyone receiving cytotoxic chemotherapy
  • People with end-stage kidney disease on maintenance hemodialysis, particularly with humanin above 759.5 pg/mL
  • Pregnancy and lactation
  • People under 18 or still growing
    •
Key Interactions
  • Growth hormone and insulin-like growth factor 1 therapy
    •
Theoretical (inferred from mechanism)
  • Cytotoxic chemotherapy (doxorubicin, bortezomib)
  • Insulin and insulin secretagogues (glipizide, repaglinide)
  • Glucocorticoids (prednisone, dexamethasone)
  • Senolytic combinations (dasatinib plus quercetin, fisetin)
  • High-dose zinc supplements
  • Glucose-lowering supplements (berberine, chromium)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Excess mortality and cardiac events at extreme circulating levels; contaminated, mislabeled or immunogenic research-grade product
    •
  • Speculative: Tumor promotion and chemoresistance; amplified senescent-cell inflammatory signaling; suppression of growth and fertility signaling; fibril formation by humanin variants
    •

Monitoring

Marker Target Why
Plasma humanin No established target; track change from the individual's own baseline Direct output of administration
Insulin-like growth factor 1 (IGF-1) Age- and sex-specific laboratory reference interval Lowered by analogue injection in rodents
Fasting plasma glucose 70–99 mg/dL Safety check for additive glucose lowering
Fasting insulin Not specified in the ER Paired with fasting glucose on the same draw
High-sensitivity C-reactive protein (hs-CRP) Below 1.0 mg/L Inflammatory markers lowered in aged mice
Prostate-specific antigen (PSA), in men No established target; track change from the individual's own baseline Safety check for tumor-promotion signal

Cadence: Glucose self-monitoring daily for the first two weeks, then a blood panel at 4 weeks, 12 weeks, and every 6 months thereafter, with age-appropriate cancer screening kept on its normal schedule

Qualitative Assessment

  • Exercise capacity and recovery between sessions
  • Cognitive clarity and short-term memory in daily tasks
  • Energy stability across the day, especially before meals
  • Injection-site appearance, swelling or persistent redness
  • Any new lump, mass or unexplained weight change
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.